360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Oxecta

Type: Product

Name: Oxecta

First reported May 14 2013 - Updated May 14 2013 - 1 reports

King Pharmaceuticals Inc

Pfizer lays off 25 in Bristol

BRISTOL, Tenn. -- Pfizer recently released about a fifth of its remaining local workforce, following a second recall of the drug Levoxyl. About 25 full-time workers at the company's Fifth Street facility were released in early May, company spokeswoman ... [Published Individual.com - May 14 2013]

Entities: Pfizer Inc, Bristol, King Pharmaceuticals Inc, Manufacturing

First reported May 13 2013 - Updated May 13 2013 - 1 reports

DURECT Corp

Pfizer's Remoxy review inflicts Pain on partner

Pfizer is weighing up whether to continue trying to get approval for Remoxy, a move which has had a disastrous effect on the stock prices of its two partners it has worked with on the abuse-resistant painkiller.Alan Litwack, Pfizer’s head of global commercial ... [Published Pharma Times - May 13 2013]

Entities: Remoxy, Pfizer Inc, DURECT Corp, Oxycodone

First reported May 06 2013 - Updated May 06 2013 - 1 reports

The Medicines Company

Court Report - May 05, 2013

About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.Eisai R&D Management Co., Ltd. v. ReaReview and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. ... [Published JD Supra - May 06 2013]

Entities: The Medicines Company, Patent, Apotex

First reported May 03 2013 - Updated May 03 2013 - 2 reports

Pfizer Inc

Acura Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript

8:30 AM ETOperatorGood morning, ladies and gentlemen, welcome to the Acura Pharmaceuticals First Quarter 2013 Results Conference Call. Just a reminder, today's call will be recorded. I would now like to turn the meeting over to Mr. Peter Clemens, Senior ... [Published Seeking Alpha - May 03 2013]

Entities: Oxecta, Acura Pharmaceuticals Inc, Pfizer Inc, Pseudoephedrine

First reported May 02 2013 - Updated May 03 2013 - 2 reports

Palatine Pharmaceutical Company Sues Over Generic Drug Plans

Acura Pharmaceuticals is suing India’s Ranbaxy for supposed patent infringement over the Indian generic drugmaker’s plans to market its version of the painkiller Oxecta. ... [Published FDA News - May 03 2013]

Entities: Generic Drug, Oxecta, Acura Pharmaceuticals Inc

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Acura Pharmaceuticals sues over generic drug plans

PALATINE -- Acura Pharmaceuticals Inc., whose technology helps deter drug abuse, sued Ranbaxy Laboratories Ltd., India’s largest drugmaker, over its plan to market a generic version of the painkiller Oxecta. ... [Published Naperville Business Ledger - May 01 2013]

Entities: Acura Pharmaceuticals Inc, Generic Drug, Oxecta, Ranbaxy Laboratories Ltd, Generic Version

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Ranbaxy Laboratories Ltd

Acura Pharmaceuticals Sues Ranbaxy Over Painkiller Drug

Acura Pharmaceuticals Inc. (ACUR), whose technology helps deter drug abuse, sued Ranbaxy Laboratories Ltd. (RBXY), India’s largest drugmaker, over its plan to market a generic version of the painkiller Oxecta.Acura, based in Palatine, Illinois, claimed ... [Published EHealth Magazine - May 01 2013]

Entities: Ranbaxy Laboratories Ltd, Acura Pharmaceuticals Inc, Drugs, Oxecta

First reported Apr 22 2013 - Updated Apr 22 2013 - 3 reports

ACURA PHARMACEUTICALS, INC.: Acura Pharmaceuticals to Host First Quarter 2013 Financial Results Conference Call on May 3, 2013

PALATINE, IL -- (Marketwired) -- 04/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company plans to report financial results for the first quarter of 2013 ... [Published 4 Traders - Apr 22 2013]

Entities: Acura Pharmaceuticals Inc, Oxecta, Pseudoephedrine, Canada, Abuse

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Stocks in Focus: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Biogen Idec Inc.(NASDAQ:BIIB)

Lakeway, NY -- (SBWIRE) -- 04/22/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) ... [Published SBWire - Apr 22 2013]

Entities: ACADIA Pharmaceuticals Inc, Acura Pharmaceuticals Inc, Biogen Idec Inc

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Decision A Boon for Abuse-Resistant Pills

Acura Pharmaceuticals Inc. benefited greatly from a decision by federal regulators to block new painkillers that aren't designed to resist abuse.Acura makes drugs that are designed to be harder to abuse. The company sells a decongestant called Nexafed ... [Published Drug Discovery and Development - Apr 18 2013]

Entities: Drugs, Zohydro, OxyContin, anodyne

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Acura Pharma rises on FDA OxyContin decision

NEW YORK -- Shares of drug developer Acura Pharmaceuticals Inc. jumped more than 50 percent Wednesday after federal regulators moved to block new painkillers that aren't designed to resist abuse.Acura makes drugs that are designed to be harder to abuse. ... [Published CNBC - Apr 17 2013]

Entities: OxyContin, Acura Pharmaceuticals Inc, FDA Food & Drug Administration, Drugs

First reported Mar 15 2013 - Updated Mar 15 2013 - 1 reports

Acura Pharmaceuticals' Universal Shelf Registration Statement Declared Effective

The universal shelf registration statement permits the Company to offer and sell, from time to time, on a continuous or delayed basis in the future, up to $75 million of equity, debt or other types of securities described in the shelf registration statement, ... [Published Stockwatch - Mar 15 2013]

Entities: Registration Statement, Oxecta, Acura Pharmaceuticals Inc, Pseudoephedrine

Quotes

...By tracking the size and price of each montha'a "s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money."

ACUR, VCLT, Has Remained On Naked Short Lists 13 Consecutive Days [Published Individual.com - May 15 2013]

"This is in response to a loss of manufacturing," Campion said. "There was a recent recall of Levoxyl -- which represents a significant portion of the work at the Bristol facility -- and production won't start up again until 2014."

Pfizer lays off 25 in Bristol [Published Individual.com - May 14 2013]

...He added that "we will be reaching out to you shortly to review high-level programme timelines and to have a confidential discussion relating to contractual terms in our current agreement"

Pfizer's Remoxy review inflicts Pain on partner [Published Pharma Times - May 13 2013]

Infringement of U S Patent Nos. 7,582,727 ( "Pharmaceutical Formulations of Bivalirudin and Process of Making the Same" issued September 1, 2009) and 7,598,343 (same title, issued October 6, 2009) following a Paragraph IV certification as part of Apotex's filing of an...

Court Report - May 05, 2013 [Published JD Supra - May 06 2013]

More Content

sort by: Date \| Relevance
Acura Pharmaceuticals Is Grossly Undervalued An... [Published Seeking Alpha - May 17 2013]
ACUR, VCLT, Has Remained On Naked Short Lists 1... [Published Individual.com - May 15 2013]
Pfizer lays off 25 in Bristol [Published Individual.com - May 14 2013]
Pfizer's Remoxy review inflicts Pain on partner [Published Pharma Times - May 13 2013]
Pfizer Having Second Thoughts on Remoxy [Published Drug Discovery and Development - May 10 2013]
Pain Therapeutics, Durect fall on Remoxy review [Published CNBC - May 10 2013]
Court Report - May 05, 2013 [Published JD Supra - May 06 2013]
Acura Pharmaceuticals Management Discusses Q1 2... [Published Seeking Alpha - May 03 2013]
Acura Pharmaceuticals reports $4 million 1Q loss [Published Chicago Daily Herald - May 03 2013]
Palatine Pharmaceutical Company Sues Over Gene... [Published FDA News - May 03 2013]
Palatine Pharmaceutical Company Sues Over Paink... [Published Palatine Patch - May 02 2013]
Why Did Pain Therapeutics Increase Over 25%? [Published Seeking Alpha - May 02 2013]
Acura Pharmaceuticals sues over generic drug plans [Published Naperville Business Ledger - May 01 2013]
Acura Pharmaceuticals Sues Ranbaxy Over Painkil... [Published EHealth Magazine - May 01 2013]
ACUR, RMTI, VCLT, Added To Naked Short Lists Today [Published Individual.com - Apr 29 2013]
ACURA PHARMACEUTICALS, INC.: Acura Pharmaceutic... [Published 4 Traders - Apr 22 2013]
Acura Pharmaceuticals to Host First Quarter 201... [Published Equities.com - Apr 22 2013]
Acura Pharmaceuticals to Host First Quarter 201... [Published Yahoo! Finance - Apr 22 2013]
Stocks in Focus: Acura Pharmaceuticals, Inc. (N... [Published SBWire - Apr 22 2013]
Society And The FDA Are Ready For Acura, Are You? [Published Seeking Alpha - Apr 20 2013]
Decision A Boon for Abuse-Resistant Pills [Published Drug Discovery and Development - Apr 18 2013]
Hot Stocks Alert: Salesforce (NYSE:CRM) and Acu... [Published SBWire - Apr 18 2013]
Acura Pharma rises on FDA OxyContin decision [Published CNBC - Apr 17 2013]
Acura Pharmaceuticals receives US patent for ab... [Published PredictWallStreet - Apr 17 2013]
Acura Pharma's abuse deterrent drug formulation... [Published PharmaBiz - Apr 08 2013]
Acura Pharmaceuticals' Universal Shelf Registra... [Published Stockwatch - Mar 15 2013]
New FDA Draft Guidance “Abuse-Deterrent Opioids... [Published FDA Law Blog - Jan 10 2013]

Blogs

sort by: Date \| Relevance
New FDA Draft Guidance “Abuse-Deterrent Opioids... [Published FDA Law Blog - Jan 10 2013] By David B. Clissold –FDA has released a Draft Guidance for Industry, titled “Abuse-Deterrent Opioids—Evaluation and Labeling.” Since at least 2005, Congress has noted the need for FDA guidance governing the development and approval of abuse-deterrent ...